TY - JOUR T1 - Alteration of Monoamine Receptor Activity and Glucose Metabolism in Pediatric Patients with Anticonvulsant-Induced Cognitive Impairment JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1490 LP - 1497 DO - 10.2967/jnumed.116.189290 VL - 58 IS - 9 AU - Yuankai Zhu AU - Jianhua Feng AU - Jianfeng Ji AU - Haifeng Hou AU - Lin Chen AU - Shuang Wu AU - Qing Liu AU - Qiong Yao AU - Peizhen Du AU - Kai Zhang AU - Qing Chen AU - Zexin Chen AU - Hong Zhang AU - Mei Tian Y1 - 2017/09/01 UR - http://jnm.snmjournals.org/content/58/9/1490.abstract N2 - A landmark study from the Institute of Medicine reported that the assessment of cognitive difficulties in children with epilepsy is timely and imperative. Anticonvulsant-induced cognitive impairment could influence the quality of life more than seizure itself in patients. Although the monoaminergic system is involved in the regulation of cognitive process, its role in anticonvulsant-induced cognitive impairment remains unclear. Methods: To explore in vivo monoamine receptor binding activity in patients with anticonvulsant-induced cognitive impairment, each patient underwent PET imaging with both monoamine receptor binding agent 11C-N-methylspiperone and glucose metabolic agent 18F-FDG. Tests of intelligence quotient (IQ), including verbal IQ (VIQ), performance IQ (PIQ), and full-scale IQ (FSIQ), were performed in each patient. Results: Compared with the patients with monotherapy, patients with polytherapy had significantly lower VIQ, PIQ, and FSIQ (P < 0.01 in each comparison), as well as significantly lower monoamine receptor activities detected in the caudate nucleus, prefrontal cortex, dorsal anterior cingulate cortex, and amygdale (P < 0.05 in each comparison). However, regarding the glucose metabolism, there was no significant difference found in patients with monotherapy or polytherapy (P > 0.05). Conclusion: Monoamine receptor PET imaging could be a promising in vivo imaging biomarker for mapping anticonvulsant-induced cognitive impairment. ER -